Composite preparation containing bovine lactoferrin and lyase and application thereof
The combined expression formulation of bovine lactoferrin and streptococcal lysin solves the problems of narrow antibacterial spectrum and purification difficulties of existing antibiotic alternatives, achieving broad-spectrum inhibition of Gram-positive and Gram-negative bacteria, especially effective inhibition of multidrug-resistant bacteria, and is suitable for large-scale production.
Patent Information
- Application Number
- CN202511476651.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-10-16
- Publication Date
- 2025-12-19
- Estimated Expiration
- 2045-10-16
AI Technical Summary
Existing antibiotic alternatives, such as probiotic preparations, antimicrobial lipopeptides, and plant extracts, have shortcomings in terms of antibacterial efficacy and antimicrobial spectrum. Bovine lactoferrin and phage lyases have problems such as protein folding errors, purification difficulties, and narrow antimicrobial spectrum, making it difficult to effectively address the challenge of multidrug-resistant bacteria.
Bovine lactoferrin and streptococcal lysin were expressed using a baculovirus-insect cell eukaryotic expression system to form a compound preparation with concentrations of 2000 μg/mL and 512 μg/mL, respectively, for broad-spectrum antibacterial activity against both Gram-positive and Gram-negative bacteria.
It achieves broad-spectrum inhibition against a variety of Gram-positive and Gram-negative bacteria, significantly improving the antibacterial efficiency, especially showing a clear antibacterial effect against multidrug-resistant Escherichia coli. It also has high protein purity, good safety, and is suitable for large-scale production.
Smart Images

Figure CN121154798A_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The present application belongs to the technical field of pharmacy, and particularly relates to a complex preparation containing bovine lactoferrin and lytic enzyme and application thereof. BACKGROUND
[0002] With the irrational use of antibiotics, the rapid spread of multi-drug resistant (MDR) bacteria has become a serious challenge in the field of global public health. To address this problem, the scientific community has extensively explored various antibiotic alternatives, many of which have been commercialized. Currently, probiotic preparations, antibacterial lipopeptides, plant extracts, plant essential oils, acidifiers, and xylo-oligosaccharides are widely used to replace antibiotics in livestock and poultry farming. However, the quality of these "alternative antibiotics" products on the market varies greatly, and their actual antibacterial effects are often unsatisfactory, making it difficult to fully meet the needs of production practice.
[0003] Bovine lactoferrin (Lactoferrin) is a natural iron-binding glycoprotein that has advantages such as broad-spectrum antibacterial, safety, and natural origin as a new type of antibacterial agent. In addition to its antibacterial effect, it also exhibits antiviral, anti-inflammatory, anticancer, and immunomodulatory functions, attracting widespread attention in recent years. However, current bovine lactoferrin is mostly produced through prokaryotic expression systems, which often results in protein folding errors and inclusion body formation, making subsequent purification difficult and reducing yield, thereby limiting its large-scale application.
[0004] Phage lysozyme has strong lytic ability against Gram-positive bacteria, but its effectiveness is significantly limited against Gram-negative bacteria due to the presence of outer membrane barriers. It usually needs to be combined with outer membrane permeabilizers or genetically engineered to exert its efficacy. In China's livestock and poultry farming, streptococcal-specific lysozyme has been applied to the prevention and control of streptococci, Staphylococcus aureus, and other pathogens, but its activity against Gram-negative bacteria is weak, and its antibacterial spectrum is narrow, which restricts its widespread application. Therefore, how to effectively enhance the antibacterial efficacy of phage lysozyme, especially to expand its activity against Gram-negative bacteria, has become a key problem to be solved.
[0005] It is worth noting that there is no research report on the strategy of using bovine lactoferrin in combination with phage lysozyme to enhance the antibacterial effect of the latter. The complementary advantages of the two may provide new ideas and approaches for the development of efficient and broad-spectrum new antibacterial agents. SUMMARY
[0006] The present application provides a complex preparation containing bovine lactoferrin and lysozyme and its application to develop new antibacterial agents.
[0007] To achieve the above-mentioned purpose, the present application provides the following technical solutions: Firstly, the application provides a composite bacteriostatic agent containing bovine lactoferrin and streptolysin, which is composed of bovine lactoferrin and streptolysin, the concentration of the bovine lactoferrin is 2000 μg / mL, and the concentration of the streptolysin is 512 μg / mL.
[0008] Preferably, the bovine lactoferrin is a protein obtained by cloning a bovine lactoferrin gene sequence SEQ ID NO. 1 into a pFastBac1 vector and then expressing by a baculovirus-insect cell eukaryotic expression system. The streptolysin is a protein obtained by cloning a streptolysin gene sequence SEQ ID NO. 2 into a pFastBac1 vector and then expressing by a baculovirus-insect cell eukaryotic expression system.
[0009] Preferably, the bacteriostatic spectrum of the composite bacteriostatic agent includes Staphylococcus aureus, Staphylococcus variabilis, Staphylococcus epidermidis, Clostridium cecum, Streptococcus suis, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus lactis, Escherichia coli and Salmonella.
[0010] Preferably, the MIC of the bacteriostatic agent for Staphylococcus aureus is 16 μg / mL, the MIC for Escherichia coli is 250 μg / mL, the MIC for Salmonella is 250 μg / mL, and the MIC for Streptococcus suis is 32 μg / mL.
[0011] Secondly, the application provides an application of a composition containing bovine lactoferrin and streptolysin in preparing a bacteriostatic agent, in the composition, the concentration of the bovine lactoferrin is 2000 μg / mL, and the concentration of the streptolysin is 512 μg / mL.
[0012] Preferably, the bovine lactoferrin is a protein obtained by cloning a bovine lactoferrin gene sequence SEQ ID NO. 1 into a pFastBac1 vector and then expressing by a baculovirus-insect cell eukaryotic expression system. The streptolysin is a protein obtained by cloning a streptolysin gene sequence SEQ ID NO. 2 into a pFastBac1 vector and then expressing by a baculovirus-insect cell eukaryotic expression system.
[0013] Preferably, the bacteriostatic spectrum of the bacteriostatic agent includes Staphylococcus aureus, Staphylococcus variabilis, Staphylococcus epidermidis, Clostridium cecum, Streptococcus suis, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus lactis, Escherichia coli and Salmonella.
[0014] Finally, the application provides a use of a composition of bovine lactoferrin and streptolysin in the preparation of a drug for inhibiting drug-resistant E. coli, wherein the concentration of the bovine lactoferrin is 2000 μg / mL, and the concentration of the streptolysin is 512 μg / mL.
[0015] Preferably, the bovine lactoferrin is a protein obtained by cloning the bovine lactoferrin gene sequence SEQ ID NO. 1 into a pFastBac1 vector and then expressing the protein through a baculovirus-insect cell eukaryotic expression system. The streptolysin is a protein obtained by cloning the streptolysin gene sequence SEQ ID NO. 2 into a pFastBac1 vector and then expressing the protein through a baculovirus-insect cell eukaryotic expression system.
[0016] Preferably, the drug-resistant bacteria are E. coli isolates that are resistant to ciprofloxacin, doxycycline, gentamicin, enrofloxacin and spectinomycin and only low-susceptible to cefixime.
[0017] The application has the following beneficial effects: Firstly, the application combines bovine lactoferrin and streptolysin to achieve the complementary advantages and synergistic effect of the two components. Single streptolysin has almost no inhibitory effect on gram-negative bacteria such as E. coli and Salmonella, and single bovine lactoferrin has limited inhibitory effect on gram-positive bacteria such as Staphylococcus aureus and Streptococcus suis. However, when the two are combined, not only can they effectively inhibit a variety of gram-positive bacteria, but they can also significantly enhance the inhibitory effect on gram-negative bacteria, achieving broad-spectrum inhibition of a variety of common pathogenic bacteria and solving the narrowness of the single component.
[0018] Secondly, the combined preparation of the application not only expands the antibacterial spectrum, but also significantly improves the antibacterial efficiency. Taking Staphylococcus aureus as an example, single streptolysin needs 12 hours to completely kill the bacteria, while the combined preparation only needs 4 hours; for E. coli, single bovine lactoferrin needs 12 hours to completely kill the bacteria, while the combined preparation completes the killing within 8 hours, greatly improving the antibacterial speed and enabling faster control of pathogenic bacterial infection.
[0019] In addition, in the face of the increasingly severe challenge of drug-resistant bacteria, the combined antibacterial preparation of the application shows great potential. In vitro experiments, single bovine lactoferrin or streptolysin cannot inhibit multi-drug-resistant E. coli, but the combined preparation can produce a clear inhibition zone. This shows that through ingenious combination, the application provides an effective alternative for the development of new drugs against drug-resistant bacteria.
[0020] Finally, the bovine lactoferritin and streptolysin of the present application are produced by a baculovirus-insect cell eukaryotic expression system, which can ensure correct folding and post-translational modification of the protein, and the obtained protein has high purity, strong activity and good safety, avoiding the problems of inclusion body and difficult purification in prokaryotic expression system, and being more conducive to large-scale production and application. BRIEF DESCRIPTION OF DRAWINGS
[0021] Figure 1 Indirect immunofluorescence test results for recombinant baculovirus packaging (a) Immunofluorescence image of streptolysin recombinant baculovirus; (b) Immunofluorescence image of bovine lactoferritin recombinant baculovirus; (c) Image of negative control group; Figure 2 SDS-PAGE and Western Blot analysis of bovine lactoferritin; Figure 3 SDS-PAGE and Western Blot analysis of streptolysin; Figure 4 Purification results of streptolysin and bovine lactoferritin; Figure 5 Bacteriostatic effect of streptolysin on gram-positive bacteria; Figure 6 Bacteriostatic effect of streptolysin on streptococcus; Figure 7 Bacteriostatic effect of bovine lactoferritin on E. coli (a) and Salmonella (b); Figure 8 Drug resistance detection of drug-resistant E. coli; Figure 9 Bacteriostatic effect of the composite preparation on drug-resistant E. coli. DETAILED DESCRIPTION
[0022] Example 1 Preparation of recombinant bovine lactoferritin and streptolysin 1.1 Gene construction and synthesis of recombinant plasmid (1) Based on the gene sequence of phage lysozyme Plyss2 and the gene sequence of bovine lactoferritin, the target gene sequence of Plyss2 gene (SEQ ID NO. 1) and the gene sequence of bovine lactoferritin (SEQ ID NO. 2) were constructed by gene modification and optimization.
[0023] (2) The optimized gene was cloned into pFastBac1 vector by using baculovirus-insect cell eukaryotic expression system, and the synthetic recombinant plasmid was synthesized, and the specific steps were as follows: The streptococcal lysin plasmid was subjected to PCR amplification with corresponding primers (the primer sequences are shown as SEQ ID NO. 3 and SEQ ID NO. 4), and the target fragment was recovered by gel electrophoresis. The target protein gene and the pFastbac-1 vector were double-digested with BamHI and EcoRI respectively to obtain the target fragment and the vector with the same cohesive ends, and then recovered by gel electrophoresis. After the recovered target gene and the pFastbac-1 vector were connected by T4 DNA ligase, a recombinant plasmid with streptococcal lysin was obtained; The plasmid carrying bovine lactoferrin was subjected to PCR amplification with corresponding primers (the primer sequences are shown as SEQ ID NO. 5 and SEQ ID NO. 6), and the target fragment was recovered by gel electrophoresis. The target protein gene and the pFastbac-1 vector were double-digested with Sal I and Not I respectively to obtain the target fragment and the vector with the same cohesive ends, and then recovered by gel electrophoresis. After the recovered target gene and the pFastbac-1 vector were connected by T4 DNA ligase, a recombinant plasmid with bovine lactoferrin was obtained; The recombinant plasmid was transformed into E. coli DH5α competent cells, and the cells were cultured at 37℃ and 200 rpm constant temperature oscillation for 12 hours; White monoclonal colonies were picked by blue-white spot screening, and the recombinant bacmid was extracted and subjected to PCR identification to screen the recombinant bacmid containing the target gene.
[0024] After the recombinant bacmid was completely dissolved, PCR was used to identify the recombinant bacmid, and the primers were designed as follows:
[0025] Note: The product size is about the size of the inserted fragment + 2300 bp.
[0026] 1.2 Packaging of recombinant baculovirus The screened recombinant bacmid was transfected into SF9 adherent cells using a transfection reagent to package the recombinant baculovirus; After 72 hours of culture, the cell supernatant was collected, and indirect immunofluorescence test was used to verify whether the packaging of the recombinant baculovirus was successful or not.
[0027] The results of the immunofluorescence test are shown in Figure 1 It can be seen from Figure 1 that (a) the streptococcal lysin recombinant baculovirus and (b) the bovine lactoferrin recombinant baculovirus have obvious immunofluorescence, while (c) the negative control group has no immunofluorescence, indicating that the streptococcal lysin recombinant baculovirus and the bovine lactoferrin recombinant baculovirus of the application are successfully packaged.
[0028] 1.3 Protein expression and verification SF9 suspension cells were infected with packaged recombinant baculovirus for in vitro protein expression, and the culture conditions were 27℃, 120 rpm; After 96 hours of culture, the cell supernatant was collected by centrifugation, and the expression of bovine lactoferritin and streptolysin was verified by SDS-PAGE and Western Blot.
[0029] The results are shown in Figure 2 and Figure 3 .
[0030] As can be seen from the results of Figure 2 and Figure 3 , the molecular weight of bovine lactoferritin is about 80 kDa, and the molecular weight of streptolysin is about 35 kDa, and the expression is successful.
[0031] 1.4 Scale-up preparation and purification By optimizing the multiplicity of infection (MOI) of recombinant baculovirus infection of SF9 suspension cells and the sampling time, the optimal expression conditions were obtained: MOI = 5, sampling time 96 hours.
[0032] The scale-up expression was carried out using a whole suspension cell bioreactor, and the culture volume was 10 L; The recombinant proteins were purified by affinity chromatography, and the purity was more than 95%. After ultrafiltration and concentration, bovine lactoferritin with a concentration of 2.4 mg / mL and streptolysin with a concentration of 1 mg / mL were obtained.
[0033] The results are shown in 4, and Figure 4 it can be seen that the streptolysin recombinant protein and the bovine lactoferrin recombinant protein were successfully purified.
[0034] Example 2 Detection of the bacteriostatic effect of streptolysin recombinant protein on gram-positive bacteria (1) Prepare TSA culture medium plates for the following strains: 26 strains of streptococcus (including 24 strains of streptococcus suis, 1 strain of streptococcus agalactiae, and 1 strain of streptococcus dysgalactiae) Staphylococcus aureus, Staphylococcus varians, and Staphylococcus epidermidis 1 strain of coccobacillus Escherichia coli, Salmonella, Pasteurella, and Actinobacillus pleuropneumoniae Each strain was streaked onto the corresponding culture medium plate and incubated at 37℃ in a biochemical incubator for 24 hours.
[0035] (2) The next day, single colonies were picked from each plate and inoculated into appropriate liquid medium. Incubate at 37℃ in a biochemical incubator for 24 hours.
[0036] (3) Prepare the culture medium plate in advance and dry it in the 37℃ incubator overnight, use the pipette to suck 100 μL of the bacterial solution and evenly spread it on the surface of the culture medium plate, evenly smear it with a sterile smear rod and dry it.
[0037] (4) Suck 2 μL of the protein sample stock solution and spot it on the plate surface (avoid the gun head to contact the culture medium, replace the gun head after each time of spotting to prevent contamination), place the culture plate vertically, and after the sample is completely absorbed, place it in the 37℃ incubator for culture for 24 hours.
[0038] (5) After the end, observe and record the results (such as Figure 5 (3 strains of Staphylococcus aureus isolates-1 / 3 / 4, 1 strain of Staphylococcus varicollis, 1 strain of Staphylococcus epidermidis and 1 strain of Clostridium clostridium) and Figure 6 as shown (1-26 are streptococci: 24 strains of Streptococcus suis (except for No. 13 and No. 16), 1 strain of Streptococcus agalactiae (No. 16), 1 strain of Streptococcus dysgalactiae (No. 13) and 1 strain of Streptococcus lactis).
[0039] From the results of Figure 5 It can be seen that the streptolysin recombinant protein prepared by the application has obvious bacteriostatic effect on clinical isolates such as Staphylococcus aureus, Staphylococcus varicollis, Staphylococcus epidermidis and Clostridium clostridium, and the bacteriostatic ring is between 8-10 mm. And for clinical isolates such as Escherichia coli, Salmonella, Pasteurella multocida and Actinobacillus pleuropneumoniae, there is no obvious bacteriostatic effect.
[0040] At the same time, from the results of Figure 6 It can be seen that the streptolysin recombinant protein prepared by the application has obvious bacteriostatic effect on 23 strains of Streptococcus suis and 1 strain of Streptococcus agalactiae, 1 strain of Streptococcus dysgalactiae and 1 strain of Streptococcus lactis.
[0041] Example 3 Determination of MIC of streptolysin recombinant protein on sensitive bacteria (1) Take a 96-well cell culture plate, use 100 μL of the pipette to add 100 μL of the corresponding broth to each well (96 wells in total). Add 100 μL of the streptolysin recombinant protein solution with an initial concentration of 512 μg / mL to the first well of each column in rows 1-8 (A1, B1, C1, D1, E1, F1, G1, H1).
[0042] (2) Use the row gun to draw 100 μL liquid from the first hole (A1-H1) of each row (A-H), transfer to the second hole, mix well, then draw 100 μL from the second hole to the third hole, and so on, continuously dilute by ratio to the tenth hole. Discard 100 μL liquid from the tenth hole. The 11th column (positive control, containing only bacterial liquid) and the 12th column (negative control, no sterile liquid, no drug) do not add drug solution.
[0043] (3) Add 10 μL of 1×10^6 CFU / mL bacterial liquid prepared in advance to each hole of the 1st to 11th columns, mix gently, so that the final bacterial liquid concentration of each hole is about 1×10^5 CFU / mL, and the 12th column does not add bacterial liquid.
[0044] (4) Seal the 96-well plate with sealing film and incubate in a 37°C air environment for 18±2 hours. Only when the positive control hole (11th column) shows sufficient bacterial growth, the results can be read. Compare the degree of bacterial growth in each hole with the positive control hole to determine the lowest drug concentration that can obviously inhibit bacterial growth, i.e. the minimum inhibitory concentration (MIC), and the results obtained are shown in Table 1.
[0045] Table 1 MIC of streptococcal lytic enzyme recombinant protein against different bacteria
[0046] As can be seen from the results in Table 1, the streptococcal lytic enzyme recombinant protein has certain antibacterial activity against Staphylococcus aureus, Streptococcus suis and Clostridium cecum, among which the inhibitory effect on Staphylococcus aureus is the best (MIC = 32 μg / mL), while the inhibitory effect on Streptococcus suis and Clostridium cecum is weaker (MIC = 64 μg / mL). These results suggest that the recombinant protein may have higher application potential in the case of Staphylococcus aureus infection, while the antibacterial effect on Streptococcus suis and Clostridium cecum may need to be further optimized or used in combination with other antibacterial agents.
[0047] Example 4 Detection of inhibitory effect of bovine lactoferrin recombinant protein on gram-negative bacteria (1) Prepare TSA or NA medium plates for resuscitation of Salmonella and Escherichia coli strains. Inoculate each strain into the corresponding medium plate by streaking and incubate in a 37°C biochemical incubator for 24 hours.
[0048] (2) The next day, pick a single colony from each plate and inoculate into an appropriate liquid medium (such as LB medium). Incubate in a 37°C biochemical incubator for 24 hours to prepare the bacterial liquid.
[0049] (3) Measure the OD600 value of the bacterial liquid and dilute it to about 1×10^6 CFU / mL with sterile medium for standby.
[0050] (4) Prepare TSA culture medium plates in advance and dry them overnight in an incubator at 37°C. Use a pipette to draw 100 μL of the adjusted bacterial solution (1×10^6 CFU / mL), spread it evenly on the surface of the culture medium plate, spread it evenly with a sterile spreader, and then let it air dry.
[0051] (5) Take 2 μL of bovine lactoferrin recombinant protein stock solution and spot it onto the surface of the plate (avoid contact between the pipette tip and the culture medium, and replace the pipette tip after each spotting to prevent contamination). Place the plate upright and, after the sample is completely absorbed, invert it and place it in a 37°C incubator for 24 hours.
[0052] (6) Observe the formation of inhibition zones on the plates, measure the diameter of the inhibition zones (unit: mm), and record the inhibitory effects on Salmonella and Escherichia coli. The results are as follows: Figure 7 As shown.
[0053] from Figure 7 The results showed that bovine lactoferrin recombinant protein (protein concentration of 2.4 mg / mL) had a significant antibacterial effect against Gram-negative bacteria, with inhibition zones of 10 mm and 12 mm against Salmonella and Escherichia coli, respectively.
[0054] Example 5 The MIC of bovine lactoferrin recombinant protein against Gram-negative bacteria was determined. (1) Take a 96-well cell culture plate and add 100 μL of the corresponding broth to each well (96 wells in total) using a 100 μL pipette. Add 100 μL of bovine lactoferrin recombinant protein solution with initial concentrations of 2400 μg / mL, 2000 μg / mL, and 1600 μg / mL to the first well of each column in rows 1-8 (A1, B1, C1, D1, E1, F1, G1, H1), respectively.
[0055] (2) Using a pipette, draw 100 μL of liquid from the first well (A1-H1) of each row (AH) and transfer it to the second well. Mix thoroughly, then draw 100 μL from the second well and transfer it to the third well, and so on, serially diluting up to the tenth well. Discard 100 μL of liquid from the tenth well. Do not add protein solution to column 11 (positive control, containing only bacterial culture) and column 12 (negative control, without sterile culture or recombinant protein solution).
[0056] (3) Add 10 μL of pre-prepared 1×10^6 CFU / mL bacterial solution to each well in columns 1 to 11, mix gently, so that the final bacterial solution concentration in each well is about 1×10^5 CFU / mL, and do not add bacterial solution to column 12.
[0057] (4) Seal the 96-well plate with sealing film and incubate in 37°C air environment for 18±2 hours. Only when the positive control well (column 11) shows sufficient bacterial growth, the results can be read. Compare the bacterial growth degree of each well with the positive control well to determine the minimum drug concentration that can obviously inhibit bacterial growth, i.e. the minimum inhibitory concentration (MIC), and the results are shown in Table 2.
[0058] Table 2 MIC of bovine milk iron recombinant protein to different bacteria
[0059] As can be seen from the results of Table 2, the bovine milk iron recombinant protein can effectively inhibit Escherichia coli and Salmonella.
[0060] Example 6 Evaluation of the antibacterial effect of a complex preparation containing streptococcal lyticase and bovine milk iron recombinant protein (1) Staphylococcus aureus, Escherichia coli, Salmonella and Streptococcus suis were streaked onto TSA or NA medium plates and incubated in a 37°C biochemical incubator for 24 hours.
[0061] (2) Single colonies were picked from each plate and inoculated into TSB liquid medium, which was incubated at 37°C for 24 hours. The OD600 value of the bacterial solution was measured, and the solution was diluted with sterile medium to 1×10^6 CFU / mL for standby.
[0062] (3) According to the formula shown in Table 3, a complex preparation of streptococcal lyticase and bovine milk iron recombinant protein was prepared and stored at 4°C.
[0063] (4) Take a 96-well cell culture plate, and use a 100 μL pipette to add 100 μL of liquid medium to each well. In column 1 (A1-H1) of each row (A-H), 100 μL of the complex preparation at different concentrations was added, respectively. 100 μL of solution was taken from each well in column 1 and transferred to column 2, and after mixing, 100 μL was taken from column 2 and transferred to column 3, and so on, and the serial dilution was continued to column 10. 100 μL was taken from column 10 and discarded, column 11 was set as the positive control (containing only bacterial solution, no protein solution), and column 12 was set as the negative control (no sterile solution, no protein solution).
[0064] (5) Add 10 μL of 1×10^6 CFU / mL bacterial solution prepared in advance to each well in columns 1 to 11, and mix gently to make the final bacterial concentration of each well about 1×10^5 CFU / mL. Column 12 was not added with bacterial solution as a negative control.
[0065] (6) Seal the 96-well plate with sealing film and incubate in 37°C air environment for 18±2 hours. After incubation, check whether the positive control well (column 11) shows sufficient bacterial growth to ensure the experiment is valid, and then compare the bacterial growth in each well with the positive control well, and record the lowest concentration of the complexed protein that can significantly inhibit bacterial growth.
[0066] Table 3 Bacteriostatic effect evaluation of streptolysin O and bovine lactoferrin recombinant proteins
[0067] As can be seen from the results in Table 3, Formula 1 (0 μg / mL streptolysin O, 2000 μg / mL bovine lactoferrin): the MICs of Staphylococcus aureus, Escherichia coli and Streptococcus suis are all 2000 μg / mL, indicating that the bacteriostatic effect of bovine lactoferrin alone is poor (high MIC value).
[0068] Formula 2 (0 μg / mL streptolysin O, 1600 μg / mL bovine lactoferrin): the MICs of Staphylococcus aureus, Escherichia coli and Salmonella are still 1600 μg / mL or invalid (MIC > 1600 μg / mL), indicating that the bacteriostatic effect is further weakened after reducing the concentration of bovine lactoferrin.
[0069] Formula 3 (512 μg / mL streptolysin O, 0 μg / mL bovine lactoferrin): the MIC of Staphylococcus aureus is 32 μg / mL, the MIC of Salmonella is 64 μg / mL, and the MICs of Escherichia coli and Streptococcus suis are invalid (MIC > 512 μg / mL), indicating that the effect of streptolysin O alone on gram-negative bacteria is limited.
[0070] Formula 4 (512 μg / mL streptolysin O, 1600 μg / mL bovine lactoferrin): the MICs are 16 μg / mL for Staphylococcus aureus, 400 μg / mL for Escherichia coli, 400 μg / mL for Salmonella, and 32 μg / mL for Streptococcus suis. Compared with Formula 5, the MICs of Escherichia coli and Salmonella are higher (400 vs 250 μg / mL), indicating that the bacteriostatic effect is slightly inferior.
[0071] Formula 6 (256 μg / mL streptolysin O, 2000 μg / mL bovine lactoferrin): the MICs are the same as those of Formula 5 (16 μg / mL for Staphylococcus aureus and 32 μg / mL for Streptococcus suis), but the MICs for Escherichia coli and Salmonella are as high as 2000 μg / mL, indicating that the bacteriostatic effect on gram-negative bacteria is significantly reduced after reducing the concentration of streptolysin O.
[0072] Formulation 7 (64 μg / mL lysing enzyme, 2000 μg / mL bovine lactoferrin): The MIC value was similar to that of formulation 6, and the MIC for E. coli and Salmonella was 2000 μg / mL, and the antibacterial effect was poor.
[0073] Only the combination of formulation 5 greatly improved the antibacterial effect on gram-negative bacilli, and the antibacterial effect of other formulations was not significantly improved.
[0074] Example 7 Evaluation of the antibacterial efficiency of the composite preparation (1) E. coli ATCC25923 and S. aureus ATCC29213 were streaked onto TSA culture medium plates and incubated at 37°C in a biochemical incubator for 24 hours.
[0075] (2) Single colonies were picked and inoculated into LB or TSB liquid medium, and incubated at 37°C with shaking (150 rpm) for 24 hours. The OD600 value of the bacterial solution was measured, and the solution was diluted with sterile medium to 1x10^6 CFU / mL for standby.
[0076] (3) Preparation of composite preparation: streptococcal lysing enzyme (512 μg / mL) and bovine lactoferrin recombinant protein (2000 μg / mL) were mixed with sterile PBS or distilled water.
[0077] Preparation of control solution: single lysing enzyme (512 μg / mL), single bovine lactoferrin (2000 μg / mL).
[0078] All solutions were prepared and used immediately, and were stored at 4°C for short-term storage.
[0079] (4) Take 96-well cell culture plates, add 100 μL TSB liquid medium to each well, and set up the experiment according to the following grouping (at least 3 replicates per group): Blank control group: only contains bacterial solution and medium, without antibacterial preparation.
[0080] Composite preparation group: add 10 μL of composite preparation (final concentration: lysing enzyme 51.2 μg / mL, bovine lactoferrin 200 μg / mL).
[0081] Single lysing enzyme group: add 10 μL of lysing enzyme solution (final concentration 51.2 μg / mL).
[0082] Single bovine lactoferrin group: add 10 μL of bovine lactoferrin solution (final concentration 200 μg / mL).
[0083] Add 10 μL of bacterial solution (1x10^6 CFU / mL) to each well, mix well, and the final bacterial solution concentration is about 1x10^5 CFU / mL.
[0084] At the same time, a negative control was set up: only medium, sterile liquid and preparation.
[0085] (5) The 96-well plate was sealed with sealing film and placed in a 37°C shaking incubator (150 rpm) for culture. Samples were taken at 2, 4, 8, 12 and 24 hours, respectively, and the OD600 value of each well was measured using a spectrophotometer to record the bacterial growth. The results are shown in Table 4.
[0086] Table 4 Evaluation of bacteriostatic results by liquid co-culture method
[0087] From the results in Table 4, it can be seen that for E. coli: Single lytic enzyme: No significant bacteriostatic effect on E. coli ATCC25923, the OD600 value continued to rise over time (3.589 at 24 hours), with no significant difference from the blank control group (OD600=3.501 at 24 hours).
[0088] Single bovine lactoferrin: showed certain bacteriostatic activity, completely inhibited bacterial growth (OD600=0) after 12 hours of co-culture, but the OD600 value was still high in the early stage (2-8 hours) (e.g. OD600=0.014 at 8 hours), indicating a slower bacteriostatic speed.
[0089] Compound preparation: showed significant synergistic bacteriostatic effect, reduced the OD600 value to 0.054 at 2 hours, and completely killed the bacteria (OD600=0) at 8 hours, which was 4 hours faster than single bovine lactoferrin.
[0090] For S. aureus ATCC29213: Single lytic enzyme: had certain bacteriostatic effect, completely killed the bacteria (OD600=0) at 12 hours, but the early bacteriostatic effect was limited (OD600=0.061 at 4 hours).
[0091] Single bovine lactoferrin: showed weak bacteriostatic activity, the OD600 value was still 0.799 at 24 hours, and it failed to completely kill the bacteria, indicating that its inhibitory effect on S. aureus was limited.
[0092] Compound preparation: the bacteriostatic effect was significantly better than that of single preparation, the OD600 value decreased to 0.025 at 2 hours, and completely killed the bacteria (OD600=0) at 4 hours, which was 8 hours faster than single lytic enzyme, showing a very significant synergistic effect.
[0093] From the above results, it can be seen that the bacteriostatic ability of streptococcal lysin and bovine lactoferrin complex preparation on E. coli ATCC25923 and S. aureus ATCC29213 is significantly better than that of single lysin or bovine lactoferrin. The complex preparation showed obvious bacteriostatic effect within 2 hours, and completely killed E. coli and S. aureus in 8 hours and 4 hours, respectively, with a much faster bacteriostatic speed than single preparation. Single lysin had no bacteriostatic effect on E. coli, and completely killed S. aureus in 12 hours; single bovine lactoferrin completely killed E. coli in 12 hours, and had weak bacteriostatic effect on S. aureus. The excellent performance of the complex preparation may be due to the synergistic effect of lysin destroying the cell wall and bovine lactoferrin interfering with bacterial metabolism, providing experimental basis for the development of high-efficiency antibacterial preparation.
[0094] Example 8 1. Drug-resistant E. coli screening (disk method) (1) The E. coli isolates were streak inoculated on MH agar plates and cultured at 37°C for 24 hours. Single colonies were picked and inoculated into LB or MH liquid medium and cultured at 37°C with shaking (150 rpm) for 24 hours. The OD600 value of the bacterial solution was measured, and the solution was diluted with sterile medium to 1×10^8 CFU / mL (about 0.5 McFarland standard).
[0095] (2) Sterile filter paper discs (6 mm in diameter) were prepared and the following antibiotic standard solutions were added to each disc (containing a standard dose): ciprofloxacin (CIP, 5 μg), doxycycline (DX, 30 μg), gentamicin (GM, 10 μg), enrofloxacin (ENR, 5 μg), spectinomycin (SPT, 100 μg), cefixime (CFM, 5 μg).
[0096] (3) 100 μL of the bacterial solution (1×10^8 CFU / mL) was evenly spread on the surface of the MH agar plate, and the sterile applicator stick was used to spread evenly and dry. The antibiotic paper discs were attached to the surface of the plate with sterile forceps (3 replicates for each antibiotic), ensuring a distance of ≥24 mm between the discs.
[0097] (4) The plate was inverted and cultured at 37°C for 24 hours, and the diameter of the bacteriostatic circle (mm) was measured.
[0098] The screening results are shown in Table 5 and Figure 8 .
[0099] Table 5 Results of in vitro bacteriostatic experiment of E. coli isolates
[0100] As can be seen from Table 5, the strain is only low-sensitive to cefixime and completely resistant to other antibiotics.
[0101] (5) Pick a single colony from the drug-resistant Escherichia coli plate, inoculate it into LB or MH liquid medium, and culture at 37°C with shaking (150 rpm) for 24 hours. Measure the OD600 value of the bacterial solution and dilute it with sterile medium to 1×10^8 CFU / mL for later use.
[0102] (6) Preparation of compound preparation: Streptococcal lysin (512 μg / mL) and bovine lactoferrin recombinant protein (2000 μg / mL) are mixed with sterile PBS or distilled water.
[0103] Prepare control group solutions: single lyase (512 μg / mL) and single bovine lactoferrin (2000 μg / mL).
[0104] (7) Prepare MH agar plates in advance, dry them overnight in an incubator at 37°C, take 100 μL of drug-resistant Escherichia coli bacterial solution (1×10^8 CFU / mL), spread it evenly on the surface of MH agar plates, spread it evenly with a sterile spreader, and then let it air dry.
[0105] (8) Use a pipette to take 2 μL of the compound preparation, single lyase, and single bovine lactoferrin and spot them on the surface of the plate (3 replicates for each preparation, with a spot spacing of ≥24 mm). Place the plate upright and incubate for 24 hours after the sample has been completely absorbed.
[0106] (9) Observe the formation of the inhibition zone on the plate and measure the diameter of the inhibition zone (mm, accurate to 0.1mm) with a vernier caliper.
[0107] The results are shown in Table 6 and Figure 9 As shown, Table 6. Evaluation of the in vitro antibacterial efficacy of the compound formulation with bovine lactoferrin and lyase against drug-resistant Escherichia coli strains.
[0108] Neither bovine lactoferrin (2000 μg / mL) nor streptococcal lysin (512 μg / mL) showed any inhibition zone (0 mm in diameter), indicating that they had no in vitro antibacterial effect against drug-resistant Escherichia coli. The compound preparation (streptococcal lysin 512 μg / mL + bovine lactoferrin recombinant protein 2000 μg / mL) produced an inhibition zone of about 8 mm against drug-resistant Escherichia coli, indicating that it has certain in vitro antibacterial activity.
[0109] Compared to cefixime (in Table 5, the inhibition zone diameter is 10 mm, indicating low sensitivity), the combined formulation showed slightly weaker antibacterial effect, but it still effectively inhibited the growth of drug-resistant bacteria, demonstrating potential antibacterial application value. Further efforts could be made to enhance the antibacterial effect of the combined formulation by increasing its concentration, thereby enabling the development of novel anti-drug-resistant bacterial agents.
Claims
1. A compound antibacterial agent containing bovine lactoferrin and streptococcal lysin, characterized in that, The compound antibacterial preparation is composed of bovine lactoferrin and streptococcal lysin, wherein the concentration of bovine lactoferrin is 2000 μg / mL and the concentration of streptococcal lysin is 512 μg / mL.
2. The compound antibacterial preparation according to claim 1, wherein the bovine lactoferrin is a protein obtained by cloning the bovine lactoferrin gene sequence SEQ ID NO.1 into the pFastBac1 vector and then expressing it through a baculovirus-insect cell eukaryotic expression system; The streptococcal lysin is a protein obtained by cloning the streptococcal lysin gene sequence SEQ ID NO.2 into the pFastBac1 vector and then expressing it through a baculovirus-insect cell eukaryotic expression system.
3. The compound antibacterial preparation according to claim 2, characterized in that, The antibacterial spectrum of the compound antibacterial preparation includes Staphylococcus aureus, Staphylococcus discoloration, Staphylococcus epidermidis, cecal cocci, Streptococcus suis, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus lactis, Escherichia coli, and Salmonella.
4. The antibacterial agent according to claim 3, characterized in that, The MIC of the antibacterial agent is 16 μg / mL against Staphylococcus aureus, 250 μg / mL against Escherichia coli, 250 μg / mL against Salmonella, and 32 μg / mL against Streptococcus suis.
5. The application of a composition containing bovine lactoferrin and streptococcal lysin in the preparation of an antibacterial agent, characterized in that, In the composition, the concentration of bovine lactoferrin is 2000 μg / mL, and the concentration of streptococcal lysin is 512 μg / mL.
6. The application according to claim 5, characterized in that, The bovine lactoferrin is a protein obtained by cloning the bovine lactoferrin gene sequence SEQ ID NO.1 into the pFastBac1 vector and then expressing it through a baculovirus-insect cell eukaryotic expression system. The streptococcal lysin is a protein obtained by cloning the streptococcal lysin gene sequence SEQ ID NO.2 into the pFastBac1 vector and then expressing it through a baculovirus-insect cell eukaryotic expression system.
7. The application according to claim 6, characterized in that, The antibacterial spectrum of the antibacterial agent includes Staphylococcus aureus, Staphylococcus discoloration, Staphylococcus epidermidis, cecal cocci, Streptococcus suis, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus lactis, Escherichia coli, and Salmonella.
8. The use of a composition of bovine lactoferrin and streptococcal lysin in the preparation of a medicament for inhibiting drug-resistant Escherichia coli, characterized in that, In the composition, the concentration of bovine lactoferrin is 2000 μg / mL, and the concentration of streptococcal lysin is 512 μg / mL.
9. The use according to claim 8, characterized in that, The bovine lactoferrin is a protein obtained by cloning the bovine lactoferrin gene sequence SEQ ID NO.1 into the pFastBac1 vector and then expressing it through a baculovirus-insect cell eukaryotic expression system. The streptococcal lysin is a protein obtained by cloning the streptococcal lysin gene sequence SEQ ID NO.2 into the pFastBac1 vector and then expressing it through a baculovirus-insect cell eukaryotic expression system.
10. The use according to claim 9, characterized in that, The drug-resistant bacteria are Escherichia coli isolates that are resistant to ciprofloxacin, doxycycline, gentamicin, enrofloxacin, and spectinomycin, but only have low sensitivity to cefixime.
Citation Information
Patent Citations
Use of bovine lactoferrin in the manufacture of a medicament for inhibiting the growth of bacteria
CN101247823A
Biofilm prevention, disruption and treatment with bacteriophage lysin
CN111803620A
Composition, preparation method and application of composition in treatment of bacterial diseases
CN113368221A
Lysostaphin variants and methods of use thereof
US20240392275A1
Broad spectrum of streptococcus lyase and use thereof
WO2016165604A1
